In vitro and in vivo considerations associated with parenteral sustained release products: A review based upon information presented and points expressed at the 2007 Controlled Release Society Annual Meeting

Journal of Controlled Release

Volumn 129, Issue 2, 2008, Pages 79-87

  Martinez, Marilyn ^a   Rathbone, Michael ^b   Burgess, Diane ^c   Huynh, Mai ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b INTERAG   (New Zealand)

^c UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMATERIAL; CARMUSTINE; CASTOR OIL; CEFTIOFUR; COTTON SEED OIL; DOXORUBICIN; DURIN; DUROS; ESTRADIOL; ESTRADIOL BENZOATE PLUS TESTOSTERONE; ESTROGEN DERIVATIVE; EXCIPIENT; FLUPHENAZINE ENANTHATE; GOSERELIN; GROWTH HORMONE; LEUPRORELIN; LEVONORGESTREL; LIPOSOME; MEDIUM CHAIN TRIACYLGLYCEROL; MEMBRYTE; MICROSPHERE; NANDROLONE DECANOATE; POLYLACTIC GLYCOLIC ACID; POLYMER; PROCAINE PENICILLIN; SESAME SEED OIL; SUFENTANIL; SYNOVEX; TESTOSTERONE ENANTATE; TRENBOLONE ACETATE; UNINDEXED DRUG; VEGETABLE OIL; VETERINARY DRUG; ZUCLOPENTHIXOL DECANOATE;

CHRONIC INFLAMMATION; CORRELATION ANALYSIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG IMPLANT; DRUG SAFETY; DRUG STABILITY; GOOD MANUFACTURING PRACTICE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INJECTION SITE FIBROSIS; INJECTION SITE INFLAMMATION; INJECTION SITE REACTION; INSTRUMENT STERILIZATION; LIPOPHILICITY; MOLECULAR WEIGHT; NONHUMAN; OSMOLARITY; PARTICLE SIZE; PRIORITY JOURNAL; REVIEW; SUSPENSION; SUSTAINED DRUG RELEASE; TOTAL QUALITY MANAGEMENT; TOXICITY TESTING; WATER CONTENT;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG COMPOUNDING; DRUG IMPLANTS; EXCIPIENTS; HUMANS; INFUSIONS, PARENTERAL; KINETICS; LIPOSOMES; MICROSPHERES; MODELS, BIOLOGICAL; MODELS, CHEMICAL; PHARMACEUTICAL SOLUTIONS; SOLUBILITY; TECHNOLOGY, PHARMACEUTICAL; VETERINARY DRUGS;

EID: 45249109321     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2008.04.004     Document Type: Review

References (67)

1. Shi Y., and Li L. Current advances in sustained-release systems for parenteral drug delivery. Expert Opin. Drug Deliv. 2 6 (2005) 1039-1058
2. Mustata G., and Dinh S.M. Drug delivery global summit-evaluating emerging technologies. Expert Opin. Drug Deliv. 2 1 (2005) 185-187
3. Matschke C., Isele U., Van Hoogevest P., and Fahr A. Sustained-release injectables formed in situ and their potential use for veterinary products. J. Control. Release 85 1-3 (2002) 1-15
4. Ahmed I., and Kasraian K. Pharmaceutical challenges in veterinary product development. Adv. Drug Deliv. Rev. 54 6 (2002) 871-882
5. Medlicott N.J., Waldron N.A., and Foster T.P. Sustained release veterinary parenteral products. Adv. Drug Deliv. Rev. 56 10 (2002) 1345-1365
6. Burgess D.J., Hussain A.S., Ingallinera T.S., and Chen M.L. Assuring quality and performance of sustained and controlled release parenterals: workshop report. AAPS PharmSci. 4 2 (2002) Article 7
7. Burgess D.J., Crommelin D.J.A., Hussain A.S., and Chen M.L. Assuring quality and performance of sustained and controlled release parenterals: EUFEPS workshop report. AAPS PharmSci. 6 1 (2004) Article 11
8. Hirano K., and Yamada H. Studies on the absorption of practically water-insoluble drugs following injection VI: subcutaneous absorption from aqueous suspensions in rats. J. Pharm. Sci. 71 5 (1982) 500-505
9. Schriftman H., and Kondritzer AA. Absorption of atropine from muscle. Am. J. Physiol. 191 3 (1957) 591-594
10. Hvidberg E., and Schou J. Subcutaneous absorption of urethane in dehydrated and fasted mice. Nature 184 (1959) 646-647
11. Porter C.J.H., and Charman S.A. Lymphatic transport of proteins after subcutaneous administration. J. Pharm. Sci. 89 3 (2000) 297-310
12. ICH Harmonized Tripartite Guideline: Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances Q6A http://www.ich.org/LOB/media/MEDIA430.pdf (1999). Accessed 02-28-08.
13. VICH Guidance for Industry: Specifications: Test Procedures and Acceptance Veterinary Drug Substances and Products: Chemical Substances VICH GL39 http://www.fda.gov/cvm/Guidance/guide176.pdf (2006). Accessed 02-18-08.
14. Food and Drug Administration/Center for Drug Evaluation and Research/Office of Pharmaceutical Sciences/Division of Product Quality Research internal report, 2001.
15. Carrascosa C., Espejo L., Torrado S., and Trrado J.J. Effect of c-sterilization process on PLGA microspheres loaded with insulin-like growth factor - I, (IGF-I). J. Biomater. Appl. 18 2 (2003) 95-108
16. Zolnik B.S., and Burgess D.J. Effect of acidic pH on PLGA microsphere degradation and release. J. Control. Release 122 3 (2007) 338-344
17. Zolnik B.S., Leary P.E., and Burgess D.J. Elevated temperature accelerated release testing of PLGA microspheres. J. Control. Release 112 3 (2006) 293-300
18. Zolnik B.S., and Burgess D.J. In Vitro-In Vivo Correlation for Parenteral Dosage Forms. In: Krishna R., and Yu L. (Eds). Biopharmaceutics Applications in Drug Development (2008), Springer Science+Business Media, Inc., New York, NY. Chapter 11 336-351
19. D'Souza S.S., and DeLuca P.P. Methods to assess in vitro drug release from injectable polymeric particulate systems. Pharm. Res. 23 3 (2006) 460-473
20. Iyer S.S., Barr W.H., and Karnes T.H. Profiling in vitro drug release from subcutaneous implants: a review of current status and potential implications on drug development. Biopharm. Drug Dispos. 27 4 (2006) 157-170
21. Soriano I., Martin A.Y., Evora C., and Sanchez E. Biodegradable implantable fluconazole delivery rods designed for the treatment of fungal osteomyelitis: influence of gamma sterilization. J. Biomed. Mater. Res. 77A 3 (2006) 632-638
22. United States Pharmacopeial Convention, Inc. Critical quality and performance parameters for modified-release parenteral dosage forms. Pharmacoperial Forum Stimuli Article 31 6 (2007)
23. Wright J.C., Tao L.S., Stevenson C.L., Beck J.C., Chen G., Jao R.M., Johnson P.A., Leonard J., and Skowronski R.J. An in vivo/in vitro comparison with a leuprolide osmotic implant for the treatment of prostate cancer. J. Control. Release 75 1-2 (2001) 1-10
24. Abazinge M., Jackson T., Yang Q., and Owusu-Ababio G. Comparison of in vitro and in vivo release characteristics of sustained release ofloxacin microspheres. Drug Deliv. 7 2 (2000) 77-81
25. Keselowsky B.G., Bridges A.W., Burns K.L., Tate C.C., Babensee J.E., Laplaca M.C., and Garcia A.J. Role of plasma fibronectin in the foreign body response to biomaterials. Biomaterials 28 25 (2007) 3626-3631
26. Anderson F.D., Archer D.F., Harman S.M., Leonard R.J., and Wilborn W.H. Tissue response to bioerodible, subcutaneous drug implants: a possible determinant of drug absorption kinetics. Pharm. Res. 10 3 (1993) 369-380
27. Huang X., and Brazel C.S. On the importance and mechanisms of burst release in matrix-controlled drug delivery systems. J. Control. Release 73 2-3 (2001) 121-136
28. Larsen S.W., Frost A.B., Ostergaard J., Marcher H., and Larsen C. On the mechanism of drug release from oil suspensions in vitro using local anesthetics as model drug compounds. Eur. J. Pharm. Sci. 34 1 (2008) 37-44
29. Larsen S.W., Jessen M.N., Ostergaard J., and Larsen C. Assessment of drug release from oil depot formulations using an in vitro model - potential applicability in accelerated release testing. Drug Dev. Ind. Pharm. 34 3 (2008) 297-304
30. Larsen S.W., Østergaard J., Friberg-Johansen H., Jessen M.N., and Larsen C C. In vitro assessment of drug release rates from oil depot formulations intended for intra-articular administration. Eur. J. Pharm. Sci. 29 5 (2006) 348-354
31. Pedersen B.T., Larsen S.W., Ostergaard J., and Larsen C. In vitro assessment of lidocaine release from aqueous and oil solutions and from preformed and in situ formed aqueous and oil suspensions. Parenteral depots for intra-articular administration. Drug Deliv. 15 1 (2008) 23-30
32. Larsen D.B., Joergensen S., Olsen N.V., Hansen S.H., and Larsen C. In vivo release of bupivacaine from subcutaneously administered oily solution, comparison with in vitro release. J. Control. Release 81 1-2 (2002) 145-154
33. D'Souza S.S., and DeLuca P.P. Development of a dialysis in vitro release method for biodegradable microspheres. AAPS PharmSciTech. 6 2 (2005) E323-E328
34. Washington C. Evaluation of non-sink dialysis methods for the measurement of drug release from colloids - effects of drug partition. Int. J. Pharm. 56 1 (1989) 71-74
35. Washington C. Drug release from microdisperse systems - a critical review. Int. J. Pharm. 58 1 (1990) 1-12
36. Hirano K., Ichihashi T., and Yamada H. Studies on the absorption of practically water-insoluble drugs following injection V: subcutaneous absorption in rats from solutions in water immiscible oils. J. Pharm. Sci. 71 5 (1982) 495-500
37. Larsen D.H., Fredholt K., and Larsen C. Assessment of rate of drug release from oil vehicle using a rotating dialysis cell. Eur. J. Pharm. Sci. 11 3 (2000) 223-229
38. Zolnik B.S., Raton J.-L., and Burgess D.J. Application of USP apparatus 4 and in situ fiber optic monitoring to microspheres release testing. Dissolution Technol. 12 2 (2005) 11-14
39. Viswanathan N.B., Patil S.S., Pandit J.K., Lele A.K., Kulkarni M.G., and Mashelkar R.A. Morphological changes in degrading PLGA and P(DL)LA microspheres: implications for the design of controlled release systems. J. Microencapsul. 18 6 (2001) 783-800
40. Guo X., and Szoka F.C. Chemical approaches to triggerable lipid vesicles for drug and gene delivery. Acc. Chem. Res. 36 5 (2003) 335-341
41. Siepmann J., Elkharraz K., Siepmann F., and Klose D. How autocatalysis accelerates drug release from PLGA-based microparticles: a quantitative treatment. Biomacromolecules 6 4 (2005) 2312-2319
42. Faisant N., Siepmann J., and Benoit J.P. PLGA-based microparticles: elucidation of mechanisms and a new, simple mathematical model quantifying drug release. Eur. J. Pharm. Sci. 15 4 (2002) 355-366
43. Wang S.H., Liang Z.H., and Zeng S. Monitoring release of ketoprofen enantiomers from biodegradable poly(d,l-lactide-co-glycolide) injectable implants. Int. J. Pharm. 373 1 (2007) 102-108
44. Lu D., Wientjes M.G., Lu Z., and Au J.L. Tumor priming enhances delivery and efficacy of nanomedicines. J. Pharmacol. Exp. Ther. 322 1 (2007) 80-88
45. Allison S.D. Liposomal drug delivery. J. Infus. Nurs. 30 2 (2007) 89-95
46. Tardi P.G., Gallagher R.C., Johnstone S., Harasym N., Webb M., Bally M.B., and Mayer L.D. Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo. Biochim. Biophys. Acta 1768 3 (2007) 678-687
47. Kirpotin D.B., Drummond D.C., Shao Y., Shalaby M.R., Hong K., Nielsen U.B., Marks J.D., Benz C.C., and Park J.W. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 66 13 (2006) 6732-6740
48. Noble C.O., Kirpotin D.B., Hayes M.E., Mamot C., Hong K., Park J.W., Benz C.C., Marks J.D., and Drummond D.C. Development of ligand-targeted liposomes for cancer therapy. Expert Opin. Ther. Targets 8 4 (2004) 335-353
49. Li W., Nicol F., and Szoka F.C. GALA: a designed synthetic pH-responsive amphipathic peptide with applications in drug and gene delivery. Adv. Drug Deliv. Rev. 56 7 (2004) 967-985
50. Fossheim S.L., Il'yasov K.A., Hennig J., and Bjørnerud A. Thermosensitive paramagnetic liposomes for temperature control during MR imaging-guided hyperthermia: in vitro feasibility studies. Acad. Radiol. 7 12 (2000) 1107-1115
51. Sawant R.M., Hurley J.P., Salmaso S., Kale A., Tolcheva E., Levchenko T.S., and Torchilin V.P. "SMART" drug delivery systems: double-targeted pH-responsive pharmaceutical nanocarriers. Bioconjug. Chem. 17 4 (2006) 943-949
52. Torchilin V.P. Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J. 119 2 (2007) E128-E147
53. Huang S., Hamilton A.J., Tiukinhoy S.D., Nagaraj A., Kane B.J., Klegerman M., McPherson D.D., and MacDonald R.C. Liposomes as ultrasound imaging contrast agents and as ultrasound-sensitive drug delivery agents. Cell. Mol. Biol. Lett. 7 2 (2002) 233-235
54. Chidambaram N., and Burgess D.J. A novel method to characterize in vitro release from submicron emulsions. AAPS PharmSci. 1 3 (1999) E11
55. Glavas-Dodov M., Goracinova K., Mladenovska K., and Fredro-Kumbaradzi E. Release profile of lidocaine HCl from topical liposomal gel formulation. Int. J. Pharm. 242 1-2 (2002) 381-384
56. Hitzman C.J., Elmquist W.F., Wattenberg L.W., and Wiedmann T.S. Development of a respirable, sustained release microcarrier for 5-fluorouracil I: in vitro assessment of liposomes, microspheres, and lipid coated nanoparticles. J. Pharm. Sci. 95 5 (2006) 1114-1126
57. FDA/CVM Guidance For Industry: Guidance for Industry Nonclinical Studies for the Safety Evaluation of Pharmaceutical Excipients (2005) http://www.fda.gov/cder/guidance/5544fnl.pdf Accessed 03-06-2008.
58. VICH Draft Guidance (#185) For Industry: Target Animal Safety for Veterinary Pharmaceutical Products VICH GL43 http://www.fda.gov/cvm/Guidance/guide185.pdf (2006) Accessed 02-28-08.
59. FDA/CVM Guidance For Industry: General Principles for Evaluating the Safety of Compounds Used in Food-Producing Animals http://www.fda.gov/cvm/guidance/gfi003.pdf (2006). Accessed 07-18-07.
60. FDA/CVM Guidance for Industry: Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: General Approach to Establish a Microbiological ADI VICH GL36 http://www.fda.gov/cvm/Guidance/guide159.pdf (2006). Accessed 02-18-08.
61. FDA/CVM Guidance for Industry: Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: Repeat-Dose (Chronic) Toxicity Testing VICH GL-37 http://www.fda.gov/cvm/Guidance/guide160.pdf Accessed 07-18-07.
62. Kompella U.B., Bandi N., and Ayalasomayajula S.P. Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression. Invest. Ophthalmol. Vis. Sci. 44 3 (2003) 1192-1201
63. Ayalasomayajula S.P., and Kompella U.B. Subconjunctivally administered celecoxib-PLGA microparticles sustain retinal drug levels and alleviate diabetes-induced oxidative stress in a rat model. Eur. J. Pharmacol. 511 2-3 (2005) 191-198
64. Amrite A.C., and Kompella U.B. Size-dependent disposition of nanoparticles and microparticles following subconjunctival administration. J. Pharm. Pharmacol. 57 12 (2005) 1555-1563
65. Morita Y., Ohtori A., Kimura M., and Tojo K. Intravitreous delivery of dexamethasone sodium m-sulfobenzoate from poly (dl-lactic acid) implants. Biol. Pharm. Bull. 21 2 (1998) 188-190
66. Kato A., Kimura H., Okabe K., Okabe J., Kunou N., and Ogura Y. Feasibility of drug delivery to the posterior pole of the rabbit eye with an episcleral implant. Invest. Ophthalmol. Vis. Sci. 45 1 (2004) 238-244
67. Okabe J., Kimura H., Kunou N., Okabe K., Kato A., and Ogura Y. Biodegradable intrascleral implant for sustained intraocular delivery of betamethasone phosphate. Invest. Ophthalmol. Vis. Sci. 44 2 (2003) 740-744